TAB08

DRUG5 trials

Sponsors

Theramab LLC

Conditions

Adult Healthy VolunteersLupus Erythematosus, SystemicPsoriasis VulgarisRheumatoid ArthritisSolid Tumors

Phase 1

Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers

CompletedNCT01885624

Theramab LLCAdult Healthy Volunteers

Start: 2011-11-30End: 2013-06-30Updated: 2017-02-15

Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis

CompletedNCT01990157

Theramab LLCRheumatoid Arthritis

Start: 2013-11-30End: 2017-02-28Updated: 2017-02-28

TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

CompletedNCT02796053

Theramab LLCPsoriasis Vulgaris

Start: 2016-04-30End: 2016-12-31Updated: 2017-02-15

Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms

CompletedNCT03006029

Theramab LLCSolid Tumors

Start: 2017-02-08End: 2019-08-13Updated: 2021-10-06

Phase 2

TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment

TerminatedNCT02711813

Theramab LLCLupus Erythematosus, Systemic

Start: 2016-03-31End: 2018-05-31Updated: 2018-05-23